US Patent

US8476413 — Sulfanyl-tetrahydropyran-based compounds and methods of their use

Method of Use · Assigned to Lexicon Pharmaceuticals Inc · Expires 2028-05-29 · 2y remaining

Vulnerability score 83/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects sulfanyl-tetrahydropyran-based compounds and their methods of use for treating diseases and disorders such as diabetes and obesity.

USPTO Abstract

Sulfanyl-tetrahydropyran-based compounds, pharmaceutical compositions comprising them, and methods of their use for the treatment of diseases and disorders such as diabetes and obesity are disclosed.

Drugs covered by this patent

Inpefa (SOTAGLIFLOZIN) · Lexicon Pharms Inc

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3628`	—	Inpefa
`U-3628`	—	Inpefa

Patent Metadata

Patent number: US8476413
Jurisdiction: US
Classification: Method of Use
Expires: 2028-05-29
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Lexicon Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.